BR112012024019A2 - forma de dosagem de liberação controlada, e, método para liberar uma droga - Google Patents

forma de dosagem de liberação controlada, e, método para liberar uma droga

Info

Publication number
BR112012024019A2
BR112012024019A2 BR112012024019A BR112012024019A BR112012024019A2 BR 112012024019 A2 BR112012024019 A2 BR 112012024019A2 BR 112012024019 A BR112012024019 A BR 112012024019A BR 112012024019 A BR112012024019 A BR 112012024019A BR 112012024019 A2 BR112012024019 A2 BR 112012024019A2
Authority
BR
Brazil
Prior art keywords
controlled release
releasing
release dosage
drug
dosage form
Prior art date
Application number
BR112012024019A
Other languages
English (en)
Other versions
BR112012024019B1 (pt
Inventor
Clark Patrick Allphin
Original Assignee
Jazz Phamaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44673619&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012024019(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jazz Phamaceuticals Inc filed Critical Jazz Phamaceuticals Inc
Publication of BR112012024019A2 publication Critical patent/BR112012024019A2/pt
Publication of BR112012024019B1 publication Critical patent/BR112012024019B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

forma de dosagem de liberação controlada, e, método para liberar uma droga. são aqui descritas formas de dosagem de liberação controlada. as formulações de liberação controlada aqui descritas fornecem liberação prolongada de drogas em dose alta que são elevadamente solúveis em água e elevadamente hidroscópicas. em modalidades específicas, formas de dosagem de liberação controlada para liberação de uma droga selecionada de ghb e sais farmaceuticamente aceitáveis, hidratos, tautômeros, solvatos e complexos de ghb. as formas de dosagem de liberação controlada aqui descritas podem incorporar tanto liberação controlada quanto liberação imediata e formulações de liberação imediata em uma única forma de dosagem unitária.
BR112012024019-6A 2010-03-24 2011-03-24 Forma de dosagem de liberação controlada para administração oral BR112012024019B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31721210P 2010-03-24 2010-03-24
US61/317,212 2010-03-24
PCT/US2011/029802 WO2011119839A1 (en) 2010-03-24 2011-03-24 Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances

Publications (2)

Publication Number Publication Date
BR112012024019A2 true BR112012024019A2 (pt) 2016-08-30
BR112012024019B1 BR112012024019B1 (pt) 2021-10-19

Family

ID=44673619

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012024019-6A BR112012024019B1 (pt) 2010-03-24 2011-03-24 Forma de dosagem de liberação controlada para administração oral

Country Status (10)

Country Link
US (9) US20120076865A1 (pt)
EP (1) EP2549987A4 (pt)
JP (1) JP5968300B2 (pt)
CN (1) CN102917697B (pt)
AU (1) AU2011232408B2 (pt)
BR (1) BR112012024019B1 (pt)
CA (1) CA2794171C (pt)
IL (1) IL222012A (pt)
MX (2) MX2020011961A (pt)
WO (1) WO2011119839A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5553830B2 (ja) 2008-07-21 2014-07-16 アルベマール・コーポレーシヨン 高含量イブプロフェンナトリウム顆粒、その調製、および非発泡性固体剤形を調製する際のその使用
US8778398B2 (en) * 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8771735B2 (en) * 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
MX2020011961A (es) 2010-03-24 2022-04-19 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas.
US20160068463A1 (en) 2012-11-14 2016-03-10 Metabolix, Inc. Production of salts of 4-hydroxybutyrate using biobased raw materials
CA2894272A1 (en) * 2012-12-14 2014-06-19 Si Group, Inc. High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms
WO2014127053A2 (en) 2013-02-13 2014-08-21 Metabolix, Inc. Process for ultra pure chemical production from biobased raw starting materials
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US20150275167A1 (en) * 2014-03-28 2015-10-01 Corning Incorporated Composition and method for cell culture sustained release
PL3131549T3 (pl) * 2014-07-09 2018-09-28 Pierre Fabre Medicament Sposób leczenia zaburzeń ruchowych przy użyciu befiradolu
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
US10398662B1 (en) * 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
FR3049463B1 (fr) * 2016-04-01 2019-07-05 Debregeas Et Associes Pharma Doses unitaires a liberation immediate de ghb ou de l'un de ses sels therapeutiquement acceptables administrees par voie orale et leur utilisation pour maintenir l'abstinence alcoolique
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11000498B2 (en) 2016-07-22 2021-05-11 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
IL275312B1 (en) 2017-12-18 2024-05-01 Tris Pharma Inc GHB pharmacy preparations containing a system that creates a floating integrated penetrating polymer network
US11337919B2 (en) 2017-12-18 2022-05-24 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive RAFT forming systems having trigger pulse drug release
WO2019126214A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
EP3727348A1 (en) * 2017-12-20 2020-10-28 Flamel Ireland Limited Packaged modified release gamma-hydroxybutyrate formulations having improved stability
CA3115122A1 (en) 2018-11-19 2020-05-28 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
KR20220133189A (ko) 2019-12-20 2022-10-04 엑스더블유파마 리미티드 4-발레릴옥시부티르산의 합성 방법
WO2021257886A1 (en) * 2020-06-18 2021-12-23 XWPharma Ltd. Controlled release granulations of water-soluble active pharmaceutical ingredients
WO2021257832A1 (en) 2020-06-18 2021-12-23 XWPharma Ltd. Pharmaceutical granulations of water-soluble active pharmaceutical ingredients
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
AU2021357705A1 (en) 2020-10-05 2023-05-18 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
TW202228666A (zh) 2020-10-16 2022-08-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 使用ghb之治療方法
TW202300139A (zh) 2021-03-19 2023-01-01 凱瑞康寧生技股份有限公司 γ-羟基丁酸衍生物的聯合釋放製劑的藥代動力學
WO2023062018A1 (en) 2021-10-11 2023-04-20 Jazz Pharmaceuticals Ireland Limited Method of administering oxybate
WO2023135150A1 (en) 2022-01-11 2023-07-20 Jazz Pharmaceuticals Ireland Limited Method of administering oxybate
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB922029A (en) 1960-05-19 1963-03-27 Equilibre Biolog L Therapeutic composition
US3051619A (en) 1960-05-19 1962-08-28 Equilibre Biolog L 4-hydroxy butyric acid therapeutic compositions and process of use for clinical sedation, hypnosis, or anaesthesia
DE1642902A1 (de) 1965-09-30 1971-05-19 Unilever Nv Verfahren zur kontinuierlichen Entsaeuerung von Glyceridoelen
US4221778A (en) 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
US4374441A (en) 1980-05-23 1983-02-22 Book Covers, Inc. Method of making a book cover and pocket element therefor
ZA814854B (en) 1980-07-17 1982-07-28 J Klosa Nonhygroscopic salts of 4-hydroxybutryric acid, methods of their production and pharmaceutical preparations containing these salts
EP0044801B1 (de) 1980-07-17 1984-02-15 Josef Dr. Klosa Nichthygroskopische Salze der 4-Hydroxybuttersäure, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Mittel
CH655507B (pt) 1983-01-12 1986-04-30
US4524217A (en) 1984-06-08 1985-06-18 Celanese Corporation Process for producing N-acyl-hydroxy aromatic amines
EP0235408B1 (en) 1984-08-06 1991-01-09 The University Of Toronto Innovations Foundation Pharmaceutical composition and treatment
IE59106B1 (en) 1985-05-31 1994-01-12 Warner Lambert Co A therapeutic effervescent composition and a method of preparing the same
US4687662A (en) 1985-08-30 1987-08-18 Warner-Lambert Company Therapeutic effervescent composition
US4738985A (en) 1986-03-19 1988-04-19 The University Of Toronto Innovations Foundations Pharmaceutical composition and treatment
DE3804168A1 (de) 1988-02-11 1989-08-24 Gewerk Eisenhuette Westfalia Planetenueberlagerungsgetriebe und ueberlagerungsantrieb fuer kettenbaender u. dgl., insbesondere fuer kettenfoerderer und kettengezogene bergbau-gewinnungsmaschinen
IT1217783B (it) 1988-06-03 1990-03-30 Farmaceutico Ct S R L Lab Impiego di salo dell,acido gamma idrossi butirrico per la preparazione di composizioni farmaceutiche adatta ad essereimpiegate nella terapia dell,alcolismo e composizioni relative
US5294430A (en) 1988-09-12 1994-03-15 University Of Rochester Use of dithiocarbamates to treat myelosuppression
US4916161A (en) 1988-10-25 1990-04-10 Bristol-Myers Squibb Taste-masking pharmaceutical agents
JP2564690B2 (ja) 1990-06-14 1996-12-18 三省製薬 株式会社 メラニン生成抑制外用剤
DE4113984C2 (de) 1991-04-29 2002-05-08 Koehler Chemie Dr Franz Salze der 4-Hydroxy-Buttersäure
DE59201238D1 (de) 1991-07-01 1995-03-02 Gerhard Gergely Reaktionsdotierte brausesysteme.
IT1271403B (it) 1993-03-26 1997-05-28 Ct Lab Farm Srl Sali dell'acido gamma-idrossibutirrico ad attivita' ansiolitica e per il trattamento degli stati depressivi
HU219462B (hu) * 1993-06-14 2001-04-28 Janssen Pharmaceutica N.V. Asztemizolt és pszeudoefedrint tartalmazó, nyújtott hatású, filmbevonatos tabletták
IT1266565B1 (it) * 1993-07-22 1997-01-09 Ct Lab Farm Srl Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
US5833599A (en) 1993-12-13 1998-11-10 Multum Information Services Providing patient-specific drug information
DE4432757A1 (de) 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
US7072840B1 (en) 1994-10-28 2006-07-04 Cybear, L.L.C. Prescription management system
US5845255A (en) 1994-10-28 1998-12-01 Advanced Health Med-E-Systems Corporation Prescription management system
GB9423542D0 (en) 1994-11-22 1995-01-11 Marples Brian A Pharmaceutical compounds
JP4072597B2 (ja) * 1994-12-27 2008-04-09 ナムローゼ・フェンノートシャップ・オルガノン 持続性製剤
US5758095A (en) 1995-02-24 1998-05-26 Albaum; David Interactive medication ordering system
US5840331A (en) 1995-06-07 1998-11-24 Arch Development Corporation Use of γ-hydroxybutyrate for the stimulation of sleep-related secretion growth hormone and prolactin
US6112182A (en) 1996-01-16 2000-08-29 Healthcare Computer Corporation Method and apparatus for integrated management of pharmaceutical and healthcare services
IT1283782B1 (it) 1996-08-09 1998-04-30 Ct Lab Farm Srl Uso di ammidi dell'acido gamma-idrossibutirrico nel trattamento di tossicodipendenze,ed in particolare sell'alcolismo
US20080292700A1 (en) * 1997-04-21 2008-11-27 Biovail Laboratories Controlled release formulations using intelligent polymers
US5990162A (en) * 1997-08-29 1999-11-23 Orphan Medical, Inc. Method for treatment of fibromyalgia and chronic fatigue syndrome
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6472432B1 (en) 1997-11-17 2002-10-29 Nicholas V. Perricone Treatment of rosacea using lipoic acid
US6014631A (en) 1998-04-02 2000-01-11 Merck-Medco Managed Care, Llc Computer implemented patient medication review system and process for the managed care, health care and/or pharmacy industry
US20010055613A1 (en) 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
EP1316309A1 (en) 1998-12-23 2003-06-04 Orphan Medical Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
WO2000038672A2 (en) 1998-12-23 2000-07-06 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
US6067524A (en) 1999-01-07 2000-05-23 Catalina Marketing International, Inc. Method and system for automatically generating advisory information for pharmacy patients along with normally transmitted data
US6565872B2 (en) 1999-02-16 2003-05-20 Xiao Yu Wu Polymeric system for drug delivery and solute separation
US6384020B1 (en) 1999-07-14 2002-05-07 Shire Laboratories, Inc. Rapid immediate release oral dosage form
WO2002024715A2 (en) 2000-09-22 2002-03-28 Orphan Medical, Inc. Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
WO2002045684A2 (en) 2000-12-06 2002-06-13 Pharmacia Corporation Rapidly dispersing pharmaceutical composition comprising effervescent agents
FR2830447B1 (fr) 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US20030180249A1 (en) 2002-03-18 2003-09-25 Khanna Satish Chandra Dosage forms for hygroscopic active ingredients
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US8216609B2 (en) * 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
RU2210360C1 (ru) 2002-09-19 2003-08-20 Общество С Ограниченной Ответственностью "Консорциум-Пик" Психотропное средство
US7668730B2 (en) 2002-12-17 2010-02-23 JPI Commercial, LLC. Sensitive drug distribution system and method
ATE482699T1 (de) 2002-12-23 2010-10-15 Merck Frosst Company Pharmazeutische zusammensetzungen und verfahren zur behandlung von morbus parkinson
US20050031688A1 (en) 2003-08-04 2005-02-10 Ayala William J. Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration
RS51934B (en) * 2003-08-08 2012-02-29 Biovail Laboratories International Srl. BUPROPION HYDROCHLORIDE TABLE WITH MODIFIED RELEASE
WO2005013944A1 (en) 2003-08-11 2005-02-17 Merck Frosst Canada Ltd. Flavored taste-masked pharmaceutical formulation made using a one-step coating process
US20050142192A1 (en) 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
CA2579576A1 (en) 2004-09-07 2006-03-16 Orphan Medical, Inc. Improved ghb compositions
US8193211B2 (en) 2004-09-30 2012-06-05 Supernus Pharmaceuticals, Inc. Controlled release compositions of gamma-hydroxybutyrate
AR051397A1 (es) 2004-10-21 2007-01-10 Novartis Ag Composicion farmaceutica
CN101098701A (zh) 2004-11-10 2008-01-02 纽约市哥伦比亚大学理事会 治疗运动障碍的方法
CN101111245A (zh) 2005-01-27 2008-01-23 阿雷姆贝克有限公司 左乙拉西坦延长释放制剂
FR2881652B1 (fr) 2005-02-08 2007-05-25 Flamel Technologies Sa Forme pharmaceutique orale microparticulaire anti-mesuage
WO2006124609A2 (en) 2005-05-16 2006-11-23 Joseph Johnson Methods and compositions for treating arg
US7645802B2 (en) * 2005-06-27 2010-01-12 Biovail Laboratories International Srl. Bupropion hydrobromide and therapeutic applications
AU2006275476A1 (en) 2005-08-01 2007-02-08 Alpharma Inc. Alcohol resistant pharmaceutical formulations
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US20090317355A1 (en) 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
US20070264346A1 (en) 2006-02-16 2007-11-15 Flamel Technologies Multimicroparticulate pharmaceutical forms for oral administration
US8309104B2 (en) * 2006-03-02 2012-11-13 Watson Pharmaceuticals, Inc. Oral controlled release formulation for sedative and hypnotic agents
KR101495146B1 (ko) 2006-03-16 2015-02-24 트리스 파마 인코포레이티드 약물 - 이온교환 수지 복합체를 함유하는 변형 방출 제제
US9023400B2 (en) 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
AU2007275034A1 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophilic abuse deterrent delivery system
US20080085304A1 (en) 2006-10-10 2008-04-10 Penwest Pharmaceuticals Co. Robust sustained release formulations
US8394845B2 (en) 2006-10-30 2013-03-12 Hanall Biopharma Co., Ltd. Method of using combination preparation comprising angiotensin-II-receptor blocker and HMG-CoA reductase inhibitor
JP2010510320A (ja) 2006-11-21 2010-04-02 マクニール−ピーピーシー・インコーポレーテツド 改変型放出鎮痛性懸濁液
AU2008207200B2 (en) 2007-01-16 2011-02-17 Egalet Ltd Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
US7568822B2 (en) 2007-03-28 2009-08-04 Visteon Global Technologies, Inc. Predictive adaptive front lighting algorithm for branching road geometry
US8202542B1 (en) 2007-05-31 2012-06-19 Tris Pharma Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US8771735B2 (en) * 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
FR2938431B1 (fr) 2008-11-14 2013-12-20 Debregeas Et Associes Pharma Nouvelle composition a base d'acide gamma-hydroxybutyrique
EP2421808B1 (en) 2009-04-23 2013-07-31 Concert Pharmaceuticals Inc. 4-hydroxybutyric acid analogs
FR2951378B1 (fr) 2009-10-16 2012-06-01 Flamel Tech Sa Forme pharmaceutique orale solide anti-mesusage et dotee d'un profil specifique de liberation modifiee
MX2020011961A (es) 2010-03-24 2022-04-19 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas.
JP2013523821A (ja) 2010-04-06 2013-06-17 アラーガン、インコーポレイテッド 前房内薬剤送達のための徐放性リザーバーインプラント
CN102905672B (zh) 2010-04-07 2016-08-17 普罗秋斯数字健康公司 微型可吞服装置
EP2386289A1 (en) 2010-04-29 2011-11-16 Ipsen Pharma S.A.S. Clay compositions
BR112012028035B1 (pt) 2010-05-04 2021-05-25 Jazz Pharmaceuticals, Inc. formulação de liberação imediata
BR112012028451A2 (pt) 2010-05-07 2016-07-19 Microdermis Corp composição tópica de iodopovidona
MX2012014549A (es) 2010-06-28 2013-02-07 Merck Patent Gmbh [1, 8]-naftiridinas sustituidas con 2, 4-diarilo como inhibidores de cinasa que se usan contra el cancer.
GB201014633D0 (en) 2010-09-02 2010-10-13 Avexxin As Rheumatoid arthritis treatment
US8617602B2 (en) 2010-09-03 2013-12-31 William Wayne Howard Immediate release compositions and methods for delivering drug formulations using weak acid ion exchange resins in abnormally high pH environments
MY161429A (en) 2010-09-30 2017-04-14 Toyama Chemical Co Ltd Sodium salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
SG188662A1 (en) 2010-09-30 2013-05-31 Toyama Chemical Co Ltd Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
US20130230587A1 (en) 2010-11-10 2013-09-05 Rubicon Research Private Limited Sustained release compositions
SG191872A1 (en) 2011-02-02 2013-08-30 Alpharma Pharmaceuticals Llc Pharmaceutical composition comprising opioid agonist and sequestered antagonist
FR2971422B1 (fr) 2011-02-11 2016-05-20 Debregeas Et Associes Pharma Granules d'acide gamma-hydroxybutyrique
BR112013020620A2 (pt) 2011-02-14 2016-10-04 Concert Pharmaceuticals Inc análogos de ácido 4-hidroxibutírico
AU2012242514A1 (en) 2011-04-15 2013-10-24 Threshold Pharmaceuticals, Inc. Unit dose form for oral administration
WO2013049161A1 (en) 2011-09-27 2013-04-04 Tepha, Inc. Controlled hydrolysis of poly-4-hydroxybutyrate and copolymers
US20160068463A1 (en) 2012-11-14 2016-03-10 Metabolix, Inc. Production of salts of 4-hydroxybutyrate using biobased raw materials
FR2999426B1 (fr) 2012-12-13 2015-01-02 Flamel Tech Sa Forme orale multiparticulaire a liberation immediate d'au moins un compose actif, comprenant des particules enrobees resistantes au broyage.
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US20150005334A1 (en) 2013-03-15 2015-01-01 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
US9801852B2 (en) 2013-08-30 2017-10-31 Jazz Pharmaceuticals, Inc. Devices and methods for facilitating and controlling use of a medication
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
SG10202004858TA (en) 2014-02-06 2020-06-29 Lan Bo Chen Composition and method for aiding sleep
EA201691582A1 (ru) 2014-02-07 2017-01-30 Оспекс Фармасьютикалз, Инк. Новые фармацевтические препараты
JP2017514903A (ja) 2014-05-01 2017-06-08 サン ファーマシューティカル インダストリーズ リミテッドＳｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｉｎｄｕｓｔｒｉｅｓ Ｌｔｄ． 徐放性懸濁組成物
US9962336B2 (en) 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Extended release suspension compositions
US20160317388A1 (en) 2014-05-01 2016-11-03 Sun Pharmaceutical Industries Limited Dual-chamber pack for extended release suspension compositions
MA41124A (fr) 2014-12-05 2017-10-10 Sun Pharmaceutical Ind Ltd Compositions en suspension à libération prolongée à rétention gastrique
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
EP3288518A4 (en) 2015-05-01 2018-12-12 Sun Pharmaceutical Industries Limited Dual-chamber pack for extended release suspension compositions
EP3478363A4 (en) 2016-02-24 2020-04-01 Chemapotheca LLC CONTROLLED RELEASE OF AMPHETAMINE, PROMOTER AND DISSUASIVE DOSAGE FORMS OF MISUSE
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11000498B2 (en) 2016-07-22 2021-05-11 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
EP3727348A1 (en) 2017-12-20 2020-10-28 Flamel Ireland Limited Packaged modified release gamma-hydroxybutyrate formulations having improved stability
CA3115122A1 (en) 2018-11-19 2020-05-28 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
CN115209885A (zh) 2019-12-24 2022-10-18 爵士制药爱尔兰有限公司 γ-羟基丁酸盐(GHB)给药

Also Published As

Publication number Publication date
US20210346300A1 (en) 2021-11-11
IL222012A (en) 2017-11-30
CA2794171A1 (en) 2011-09-29
AU2011232408A1 (en) 2012-10-11
CN102917697A (zh) 2013-02-06
US20200397706A1 (en) 2020-12-24
US11090269B1 (en) 2021-08-17
US10987310B2 (en) 2021-04-27
CN102917697B (zh) 2016-01-20
US20220096384A1 (en) 2022-03-31
US20200113840A1 (en) 2020-04-16
US20200330389A1 (en) 2020-10-22
US20180318222A1 (en) 2018-11-08
US10959956B2 (en) 2021-03-30
US10758488B2 (en) 2020-09-01
AU2011232408B2 (en) 2015-07-30
US20210244670A1 (en) 2021-08-12
US20120076865A1 (en) 2012-03-29
US10813885B1 (en) 2020-10-27
MX2020011961A (es) 2022-04-19
EP2549987A4 (en) 2015-01-21
US11207270B2 (en) 2021-12-28
JP5968300B2 (ja) 2016-08-10
WO2011119839A1 (en) 2011-09-29
EP2549987A1 (en) 2013-01-30
US10966931B2 (en) 2021-04-06
US20200397705A1 (en) 2020-12-24
JP2013522373A (ja) 2013-06-13
MX2012011022A (es) 2013-02-26
BR112012024019B1 (pt) 2021-10-19
CA2794171C (en) 2018-07-03

Similar Documents

Publication Publication Date Title
BR112012024019A2 (pt) forma de dosagem de liberação controlada, e, método para liberar uma droga
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
CL2012000754A1 (es) Compuestos derivados de benzoxazepina condensadas con pirazolilo o imidazolilo, inhibidores de la actividad de la quinasa pi3; composicion farmaceutica que comprende un compuesto; y su uso en la preparacion de medicamentos para el tratamiento del cancer.
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
UY31918A (es) Compuestos de pirazol inhibidores de fgfr, composiciones farmaceuticas que los comprenden, procesos para su preparacion y su uso como medicamento
BR112015008365A2 (pt) composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
BR112016001678A2 (pt) Composição, método de fabricação de um comprimido, comprimido, forma de dosagem unitária, artigo de fabricação, e, uso de uma composição, de um comprimido ou de uma forma de dosagem unitária
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
AR122580A2 (es) Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
AR088232A1 (es) Composiciones farmaceuticas
AR085173A1 (es) Terapia de combinacion para el tratamiento de enfermedades oncologicas y fibroticas
UA118261C2 (uk) Хімічні сполуки
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
ATE530170T1 (de) Paliperidonformulierung mit verzögerter freisetzung
PH12016502353A1 (en) Pharmaceutical composition
TW201613577A (en) Pharmaceutical combinations
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
SV2010003752A (es) Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/03/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.